$IGC
IGC Pharma Inc Stock $igc

$igc Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000118518524000650 Filed on June 24, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2024
Revenue	$272.0K	$295.0K	$1.345M
YoY Change	-50.99%	77.71%	47.64%
Cost Of Revenue	$109.0K	$124.0K	$612.0K
YoY Change	-63.67%	20.39%	30.49%
Gross Profit	$163.0K	$171.0K	$733.0K
YoY Change	-36.08%	171.43%	65.84%
Gross Profit Margin	59.93%	57.97%	54.5%
Selling, General & Admin	$1.670M	$1.232M	$6.758M
YoY Change	1.4%	-61.89%	-17.34%
% of Gross Profit	1024.54%	720.47%	921.96%
Research & Development	$889.0K	$855.0K	$3.800M
YoY Change	19.01%	73.43%	9.79%
% of Gross Profit	545.4%	500.0%	518.42%
Depreciation & Amortization	$162.0K	$164.0K	$637.0K
YoY Change	4.52%	7.19%	-3.04%
% of Gross Profit	99.39%	95.91%	86.9%
Operating Expenses	$2.559M	$2.087M	$10.56M
YoY Change	6.89%	-43.99%	-9.27%
Operating Profit	-$2.396M	-$1.916M	-$9.798M
YoY Change	12.01%	-47.69%	-12.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$18.00K	$7.000K	$143.0K
YoY Change	-71.88%	-22.22%	120.0%
Pretax Income	-$2.378M	-$2.885M	-$13.00M
YoY Change	14.6%	-28.41%	12.98%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$2.378M	-$2.885M	-$13.00M
YoY Change	14.6%	-28.41%	12.98%
Net Earnings / Revenue	-874.26%	-977.97%	-966.54%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.03	-$0.04	-$0.22
COMMON SHARES
Basic Shares Outstanding	75.64M shares	63.73M shares	58.84M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.824M	$1.198M	$1.198M
YoY Change	-6.46%	-64.24%	-64.24%
Cash & Equivalents	$1.824M	$1.200M	$1.198M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$240.0K	$115.0K	$876.0K
YoY Change	24.35%	-65.57%	162.28%
Inventory	$1.510M	$1.540M	$1.540M
Prepaid Expenses
Receivables	$28.00K	$39.00K	$39.00K
Other Receivables	$51.00K	$52.00K	$52.00K
Total Short-Term Assets	$4.407M	$3.705M	$3.705M
YoY Change	-13.21%	-42.7%	-42.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.586M	$3.695M	$3.893M
YoY Change	-55.75%	-56.73%	-54.41%
Goodwill
YoY Change
Intangibles	$1.720M	$1.616M
YoY Change	45.89%	38.12%
Long-Term Investments
YoY Change
Other Assets	$688.0K	$688.0K	$688.0K
YoY Change	-32.35%	-31.41%	-31.41%
Total Long-Term Assets	$6.187M	$6.197M	$6.197M
YoY Change	-41.6%	-42.15%	-42.15%
TOTAL ASSETS
Total Short-Term Assets	$4.407M	$3.705M	$3.705M
Total Long-Term Assets	$6.187M	$6.197M	$6.197M
Total Assets	$10.59M	$9.902M	$9.902M
YoY Change	-32.41%	-42.36%	-42.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$771.0K	$773.0K	$773.0K
YoY Change	14.73%	45.85%	45.85%
Accrued Expenses	$1.718M	$1.567M	$940.0K
YoY Change	17.75%	108.38%	25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$3.000K	$3.000K	$0.00
YoY Change	0.0%
Long-Term Debt Due	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$2.489M	$2.340M	$2.340M
YoY Change	16.8%	23.29%	23.29%
LONG-TERM LIABILITIES
Long-Term Debt	$136.0K	$137.0K	$137.0K
YoY Change	-2.86%	-2.84%	-2.84%
Other Long-Term Liabilities	$20.00K	$20.00K	$104.0K
YoY Change	-4.76%	-91.23%	-54.39%
Total Long-Term Liabilities	$225.0K	$241.0K	$241.0K
YoY Change	-33.82%	-34.69%	-34.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.489M	$2.340M	$2.340M
Total Long-Term Liabilities	$225.0K	$241.0K	$241.0K
Total Liabilities	$2.714M	$2.581M	$2.581M
YoY Change	9.83%	13.85%	13.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.0M	-$113.7M
YoY Change	12.95%	12.91%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.880M	$7.321M	$7.321M
YoY Change
Total Liabilities & Shareholders Equity	$10.59M	$9.902M	$9.902M
YoY Change	-32.41%	-42.36%	-42.36%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2024
OPERATING ACTIVITIES
Net Income	-$2.378M	-$2.885M	-$13.00M
YoY Change	14.6%	-28.41%	12.98%
Depreciation, Depletion And Amortization	$162.0K	$164.0K	$637.0K
YoY Change	4.52%	7.19%	-3.04%
Cash From Operating Activities	-$1.752M	-$526.0K	-$5.199M
YoY Change	19.35%	-65.33%	-26.22%
INVESTING ACTIVITIES
Capital Expenditures	$38.00K	$325.0K	$138.0K
YoY Change	90.0%	-31.58%	-77.71%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.000K	$198.0K
YoY Change	-100.0%	-99.14%	-48.44%
Cash From Investing Activities	-$131.0K	-$323.0K	-$317.0K
YoY Change	2520.0%	33.47%	34.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$3.027M
YoY Change			2838.83%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.507M	667.0K	$3.524M
YoY Change	-250800.0%	-66800.0%	3424.0%
NET CHANGE
Cash From Operating Activities	-$1.752M	-526.0K	-$5.199M
Cash From Investing Activities	-$131.0K	-323.0K	-$317.0K
Cash From Financing Activities	$2.507M	667.0K	$3.524M
Net Change In Cash	$626.0K	-182.0K	-$1.998M
YoY Change	-142.5%	-89.66%	-72.18%
FREE CASH FLOW
Cash From Operating Activities	-$1.752M	-$526.0K	-$5.199M
Capital Expenditures	$38.00K	$325.0K	$138.0K
Free Cash Flow	-$1.790M	-$851.0K	-$5.337M
YoY Change	20.3%	-57.28%	-30.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Other Receivables OtherReceivables	951000	usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-32830
CY2024	dei	Entity Registrant Name EntityRegistrantName	IGC PHARMA, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MD
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2760393
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	10224 Falls Road
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Potomac
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20854
CY2024	dei	City Area Code CityAreaCode	301
CY2024	dei	Local Phone Number LocalPhoneNumber	983-0998
CY2024	dei	Security12b Title Security12bTitle	Common Stock
CY2024	dei	Trading Symbol TradingSymbol	IGC
CY2024	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	20882737	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	75636419	shares
CY2024	dei	Auditor Firm AuditorFirmId	5341
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1198000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3196000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	107000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	154000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1540000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2651000	usd
CY2024Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	720000	usd
CY2023Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	208000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	358000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	3705000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	6466000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1616000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1170000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3695000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8213000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1003000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	326000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	6197000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	10712000	usd
CY2024Q1	us-gaap	Assets Assets	9902000	usd
CY2023Q1	us-gaap	Assets Assets	17178000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	773000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	530000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1567000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1368000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2340000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1898000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	137000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	141000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	84000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	207000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	241000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	369000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	2581000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2267000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66691195	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66691195	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53077436	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53077436	shares
CY2024Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	124409000	usd
CY2023Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	118965000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3423000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3389000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113665000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100665000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7321000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	14911000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9902000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17178000	usd
CY2024	us-gaap	Revenues Revenues	1345000	usd
CY2023	us-gaap	Revenues Revenues	911000	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	612000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	469000	usd
CY2024	us-gaap	Gross Profit GrossProfit	733000	usd
CY2023	us-gaap	Gross Profit GrossProfit	442000	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6758000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8552000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3773000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3461000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-9798000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-11571000	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	3345000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	143000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	65000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11506000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-13000000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-11506000	usd
CY2024	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-34000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-421000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13034000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11927000	usd
CY2024	igc	Earnings Per Share Basic Diluted EarningsPerShareBasicDiluted	-0.22
CY2023	igc	Earnings Per Share Basic Diluted EarningsPerShareBasicDiluted	-0.22
CY2024	igc	Weighted Average Number Of Share Outstanding Basic Diluted WeightedAverageNumberOfShareOutstandingBasicDiluted	58839868	shares
CY2023	igc	Weighted Average Number Of Share Outstanding Basic Diluted WeightedAverageNumberOfShareOutstandingBasicDiluted	52576258	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	23892000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2843000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	103000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11506000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-421000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	14911000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	14911000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1917000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3027000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	500000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-13000000	usd
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-34000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7321000	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-13000000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-11506000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	637000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	657000	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	93000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	126000	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3448000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1773000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2843000	usd
CY2024	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	44000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-39000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5000	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1008000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-897000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-150000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-591000	usd
CY2024	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-315000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	150000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	243000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-451000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	197000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-88000	usd
CY2024	igc	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-129000	usd
CY2023	igc	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-124000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-123000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-134000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5199000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7047000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	310000	usd
CY2024	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	44000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	538000	usd
CY2024	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-154000	usd
CY2023	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	154000	usd
CY2024	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	377000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	309000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-317000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-235000	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3027000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103000	usd
CY2024	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2024	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-3000	usd
CY2023	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-3000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3524000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-6000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-82000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1998000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7264000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3196000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10460000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1198000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3196000	usd
CY2024	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	1773000	usd
CY2023	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	2843000	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 1 </b>–<b> NATURE OF OPERATIONS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IGC Pharma is on a mission to transform Alzheimer’s treatment. We are building a robust pipeline of five drug candidates, each targeting different aspects of the disease.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tr> <td style="width:18pt;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>IGC-AD1</b>: Our lead investigational drug tackles agitation, a major burden for patients and caregivers. By addressing neuroinflammation, it offers a faster-acting solution compared to traditional medications.</p> </td> </tr> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tr> <td style="width:18pt;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TGR-63</b>: Through pre-clinical studies, TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark.</p> </td> </tr> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tr> <td style="width:18pt;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>IGC-1C</b>: At the preclinical stage, IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course.</p> </td> </tr> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tr> <td style="width:18pt;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>IGC-M3</b>: Also in preclinical development, IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline.</p> </td> </tr> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tr> <td style="width:18pt;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>LMP</b>: In preclinical development, LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect.</p> </td> </tr> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are also harnessing the power of Artificial Intelligence (“AI”) to develop early detection models, optimize clinical trials, and explore new applications for our drugs including for IGC-AD1. Additionally, our 28 patent filings, including for IGC-AD1, demonstrates our commitment to innovation and protecting our intellectual property.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of March 31, 2024, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), IGCare LLC, HH Processors, LLC, IGC Pharma, LLC, SAN Holdings, LLC, Sunday Seltzer, LLC, Hamsa Biopharma India Pvt. Ltd. And Colombia-based beneficially-owned subsidiary IGC Pharma SAS. The Company’s fiscal year is the 52- or 53-week period that ends on March 31. The Company’ principal office is in Maryland established in 2005. Additionally, the Company has offices in Washington state, Colombia, South America, and India. The Company’s filings are available on www.sec.gov.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">IGC has two segments: Life Sciences Segment and Infrastructure Segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Life Sciences Segment</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IGC Pharma, a clinical-stage company developing treatments for Alzheimer's disease, is committed to transforming patient care by offering faster-acting and more effective solutions. Our lead drug, IGC-AD1, embodies this vision by tackling a critical challenge – managing agitation in Alzheimer's dementia. Early results from our Phase 2 trial are promising: IGC-AD1 effectively reduced agitation in patients compared to a placebo, and crucially, it did so much faster than traditional medications. While existing anti-psychotics can take a long 6 to 12 weeks to show effects, IGC-AD1 has the potential to act within two weeks. This significantly faster onset of action could significantly improve patient care and represents a potential breakthrough in managing Alzheimer's-related agitation. In addition, we have created in-house wellness brands, available through online channels that are compliant with relevant federal, state, and local laws and regulations. We derive revenue from our in-house wellness non-pharmaceutical formulations that are manufactured as non-GMO, vegan, products at our facility and are sold over-the-counter (“OTC”).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Infrastructure Segment</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s infrastructure business has been operating since 2008, it includes (i) Execution of Construction Contracts and (ii) Rental of Heavy Construction Equipment.</p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>b) Use of estimates</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management believes that the estimates and assumptions used in the preparation of the consolidated financial statements are prudent and reasonable. Significant estimates and assumptions are generally used for, but not limited to, allowance for uncollectible accounts receivable; sales returns; normal loss during production; future obligations under employee benefit plans; the useful lives of property, plant, and equipment; intangible assets; valuations; impairment of goodwill and investments; recoverability of advances; the valuation of options granted, and warrants issued; and income tax and deferred tax valuation allowances, if any. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Critical accounting estimates could change from period to period and could have a material impact on IGC’s results, operations, financial position, and cash flows. Changes in estimates are reflected in the financial statements in the period in which changes are made, and if material, their effects are disclosed in the notes to the consolidated financial statements.</p>
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58839868	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52576258	shares
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	358000	usd
CY2024	igc	Going Concern Policy Policy Textblock GoingConcernPolicyPolicyTextblock	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>f) Going Concern:</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, "<i>Presentation of Financial Statements</i>—<i>Going Concern</i>", which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur significant operating and net losses and negative cash flows from operations in the near future.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the years ended March 31, 2024, and March 31, 2023, the Company incurred net losses of $13 million and $11.5 million, respectively. As of March 31, 2024, the Company’s cash and cash equivalents totaled $1.2 million. On June 30, 2023, the Company successfully obtained a working capital facility totaling approximately $12 million for one year, and the Company is in the process of renewing the facility for another year during the month of June 2024. In addition, on March 22, 2024, the Company entered into a share purchase agreement relating to the sale and issuance by our company to the investors of an aggregate of approximately 8.8 million shares of our common stock, for a total purchase price of $3 million or $0.34 per share, subject to the terms and subject to the conditions set forth in the 2024 SPA. As of March 31, 2024, the Company received $500 thousand, and the remaining $2.5 million was received in April 2024. The equity and the credit facility serve to minimize ongoing liquidity requirements and ensure the Company’s ability to sustain its operations. Furthermore, the Company intends to raise additional funds through private placement and ATM offerings, subject to market conditions. Please refer to Note 19, “Subsequent Event,” for further information.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company estimates that its current cash and cash equivalents balance with working capital and equity investment is sufficient to support operations beyond the twelve months following the date these consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.</p>
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-13000000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11500000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	12000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3000000	usd
CY2024	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	39000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24000	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	107000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	17000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1200000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3200000	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>m) Concentration of credit risk and significant customers</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Financial instruments, which potentially expose the Company to concentrations of credit risk, are primarily comprised of cash and cash equivalents, investments, accounts receivable, and unbilled accounts receivable, if any. The Company places its cash investments in highly rated financial institutions. The Company adheres to a formal investment policy with the primary objective of preservation of principal, which contains credit rating minimums and diversification requirements. Management believes its credit policies reflect normal industry terms and business risk. The Company does not anticipate non-performance by the counterparties and, accordingly, does not require collateral. During Fiscal 2024, sales were spread across customers in Asia and U.S., and the credit concentration risk is low.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q1	igc	Statutory Advances StatutoryAdvances	39000	usd
CY2023Q1	igc	Statutory Advances StatutoryAdvances	25000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3800000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3500000	usd
CY2023Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	24000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	115000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	262000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	208000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1099000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2100000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	18000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	441000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	533000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1540000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2651000	usd
CY2024	us-gaap	Inventory Write Down InventoryWriteDown	1000000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	376000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	41000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	72000	usd
CY2024Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	52000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	181000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	107000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	689000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	636000	usd
CY2024Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	927000	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	534000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1616000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1170000	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	74000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	57000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	82000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	90000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	99000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	109000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	120000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6137000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10149000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2442000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1936000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3695000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8213000	usd
CY2024	us-gaap	Depreciation Depreciation	563000	usd
CY2023	us-gaap	Depreciation Depreciation	417000	usd
CY2024Q1	us-gaap	Land Land	720000	usd
CY2023Q1	us-gaap	Land Land	4100000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	132000	usd
CY2024Q1	us-gaap	Other Receivables OtherReceivables	686000	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	27000	usd
CY2024Q1	igc	Other Advances OtherAdvances	0	usd
CY2023Q1	igc	Other Advances OtherAdvances	25000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1003000	usd
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	178000	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	141000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	148000	usd
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	178000	usd
CY2024	us-gaap	Lease Cost LeaseCost	241000	usd
CY2023	us-gaap	Lease Cost LeaseCost	326000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	326000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	326000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	84000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	207000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	208000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	340000	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	140000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	118000	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	198000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	326000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	87000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	208000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	816000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	619000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	208000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	258000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	124000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	133000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	419000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	358000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1567000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1368000	usd
CY2024Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	25000	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	31000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	3000	usd
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	3000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0375	pure
CY2020Q2	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	731000	usd
CY2020Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30Y
CY2024	us-gaap	Interest Expense Debt InterestExpenseDebt	5000	usd
CY2024	us-gaap	Repayments Of Debt RepaymentsOfDebt	3000	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	137000	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	3000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	20000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	21000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.06	pure
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66691195	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024	igc	Units Outstanding UnitsOutstanding	91472	shares
CY2024	igc	Unit Description UnitDescription	Ten units may be separated into one share of common stock.
CY2021Q1	igc	Sales Agreement Maximum SalesAgreementMaximum	60000000	usd
CY2024Q1	us-gaap	Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares	7600000	shares
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	4600000	usd
CY2024	igc	Weighted Average Price Per Share WeightedAveragePricePerShare	0.61
CY2024	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	4900000	shares
CY2024	igc	Exercised Weighted Average Grant Date Fair Value ExercisedWeightedAverageGrantDateFairValue	0
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0524	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0242	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.75	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.82	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4429000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.01
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5848000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.28
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	2535000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.58
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	290000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0.31
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7452000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.61
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	150000	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.46
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.39
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3560000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.24
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.27
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3710000	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.25
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
CY2024	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	1198000	usd
CY2024	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	0	usd
CY2024	us-gaap	Fair Value Assets And Liabilities Measured On Recurring Basis Gain Loss Included In Earnings FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings	0	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1198000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1198000	usd
CY2024Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	0	usd
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	3348000	usd
CY2023	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	2000	usd
CY2023	us-gaap	Fair Value Assets And Liabilities Measured On Recurring Basis Gain Loss Included In Earnings FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings	0	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	3350000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3196000	usd
CY2023Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	154000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11506000	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2730000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2416000	usd
CY2024	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	151000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	7000	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1475000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-667000	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	88000	usd
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1406000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3002000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2023	us-gaap	Revenues Revenues	911000	usd
CY2023	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1616000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	287000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	137000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	14272000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	12888000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	418000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	548000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14977000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13573000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14977000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13573000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	69101000	usd
CY2024Q1	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	4542000	usd
CY2024	us-gaap	Revenues Revenues	1345000	usd
CY2023	us-gaap	Revenues Revenues	911000	usd
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2024	us-gaap	Revenues Revenues	1345000	usd
CY2024	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2023	us-gaap	Revenues Revenues	911000	usd
CY2023	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2024	us-gaap	Revenues Revenues	1345000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3695000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	6197000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1170000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8213000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1003000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	326000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	10712000	usd
CY2024	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	dei	Auditor Name AuditorName	Manohar Chowdhry & Associates
CY2024	dei	Auditor Location AuditorLocation	Chennai, India
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001326205

Files In Submission

Name	View Source	Status
0001185185-24-000650-index-headers.html	Edgar Link	pending
0001185185-24-000650-index.html	Edgar Link	pending
0001185185-24-000650.txt	Edgar Link	pending
0001185185-24-000650-xbrl.zip	Edgar Link	pending
ex_691484.htm	Edgar Link	pending
ex_691485.htm	Edgar Link	pending
ex_691486.htm	Edgar Link	pending
ex_691487.htm	Edgar Link	pending
ex_691488.htm	Edgar Link	pending
ex_691489.htm	Edgar Link	pending
ex_691490.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
igc-20240331.xsd	Edgar Link	pending
igcpharma20240331_10k.htm	Edgar Link	pending
igcpharma20240331_10kimg001.jpg	Edgar Link	pending
igcpharma20240331_10kimg002.jpg	Edgar Link	pending
igcpharma20240331_10kimg003.jpg	Edgar Link	pending
igcpharma20240331_10kimg004.jpg	Edgar Link	pending
igcpharma20240331_10kimg005.jpg	Edgar Link	pending
igcpharma20240331_10kimg006.jpg	Edgar Link	pending
igcpharma20240331_10kimg007.jpg	Edgar Link	pending
igcpharma20240331_10kimg008.jpg	Edgar Link	pending
igcpharma20240331_10kimg009.jpg	Edgar Link	pending
igcpharma20240331_10kimg010.jpg	Edgar Link	pending
igcpharma20240331_10kimg011.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
igc-20240331_cal.xml	Edgar Link	unprocessable
igc-20240331_def.xml	Edgar Link	unprocessable
igc-20240331_lab.xml	Edgar Link	unprocessable
igc-20240331_pre.xml	Edgar Link	unprocessable
igcpharma20240331_10k_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IGC
IGC Pharma Inc Stock $igc

2024 Q2 Form 10-K Financial Statement

#000118518524000650 Filed on June 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IGC IGC Pharma Inc Stock $igc

2024 Q2 Form 10-K Financial Statement

#000118518524000650 Filed on June 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IGC
IGC Pharma Inc Stock $igc